Merck Lines Up $240M Alydia Health Buyout To Beef Up Women's Health Spin-Off

  • Shortly after unveiling plans to spin its women’s health portfolio into the new company Organon, Merck & Co Inc MRK has lined up a buyout deal to get the new company started. It filed Form 10 related to the spin-off earlier this month.
  • Organon has struck an up to $240 million deal to acquire Alydia Health that makes a device designed to prevent a mother’s death during childbirth.
  • The company’s Jada device is designed to treat postpartum hemorrhage, the excessive bleeding that can follow childbirth.
  • The device will be a part of Organon’s portfolio of contraceptive implants and removable birth control, including Nexplanon and NuvaRing, as well as a line of biosimilar drugs developed with Samsung Bioepis.
  • Organon’s products posted 2020 revenues of $6.5 billion, but this represents a drop from 2019’s $7.8 billion and 2018’s $8.3 billion.
  • First, a $50 million upfront deposit from Merck, followed by $165 million from Organon once it is on its own, is expected before the end of June. An additional $25 million in potential milestones brings the total to $240 million.
  • Price Action: MRK shares are down 1.38% at $77.2 in market hours on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsM&ANewsHealth CareGeneralwomen's health
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!